STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SUTRO BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.26+0.32 (+2.88%)
Close on Oct 19, 2026
- Market cap
- $186.51M
- P/E (TTM)
- –
- Dividend yield
- –
Sutro Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Market Cap | $186.62M | $166.30M |
| Enterprise Value | $22.28M | $88.19M |
| PS Ratio | 4.08 | 3.65 |
Enterprise value
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| EV / Sales | 0.49 | 2.51 |
Income (trailing twelve months)
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Revenue | $45.70M | $58.34M |
| Operating Income | -$146.05M | -$21.40M |
| Pretax Income | -$180.73M | -$14.34M |
| Net Income | -$180.64M | -$22.46M |
| EBITDA | -$139.99M | -$16.91M |
| EPS (Diluted) | -$17.32 | -$0.83 |
Margins
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Operating Margin | -319.6% | -44.0% |
| Pretax Margin | -395.5% | -13.3% |
| Profit Margin | -395.2% | -40.2% |
| EBITDA Margin | -306.3% | -30.2% |
Returns
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -79.1% | -40.9% |
| Return on Capital Employed (ROCE) | -103.2% | -38.1% |
Growth
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -56.3% | 5.96% |
| Revenue Growth (3Y CAGR) | 14.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 19.1% | 6.48% |
Balance sheet
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $164.35M | $61.43M |
| Net Cash (Debt) | $164.35M | $15.35M |
| Net Cash Per Share | $9.91 | $0.66 |
| Equity (Book Value) | -$103.32M | $49.09M |
| Book Value Per Share | -$6.23 | $1.37 |
| Tangible Book Value | -$103.32M | $23.52M |
| Working Capital | $122.75M | $76.81M |
Financial position
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Current Ratio | 3.32 | 3.34 |
| Quick Ratio | 3.22 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$145.17M | -$12.35M |
Efficiency
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Asset Turnover | 0.20 | 0.39 |
| Revenue Per Employee | $333.59K | $404.87K |
| Profits Per Employee | -$1.32M | -$703.34K |
| Employee Count | 137 | 74 |
Dividends and yields
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -96.8% | -23.3% |
Shares
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 16,581,200 | 58,127,000 |
| Shares Change (YoY) | 39.7% | 10.9% |
| Shares Change (QoQ) | 0.06% | 0.54% |
| Float | 15,569,200 | 49,136,700 |
| Shares Held by Insiders | 6.10% | 11.6% |
| Shares Held by Institutions | 99.4% | 59.4% |
Taxes
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Income Tax | -$96.00K | $79.87K |
Scores
| Measure | Sutro Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | -8.71 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Sutro Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.